Site-specific in situ generation of allicin using a targeted...

Details Site-specific in situ generation of allicin using a targeted... Site-specific in situ generation of allicin using a targeted...

2001-12-26

2008-11-04

Helms, Larry (Department: 1642)

Drug, bio-affecting and body treating compositions

Plant material or plant extract of undetermined constitution...

Containing or obtained from allium

C424S178100, C424S182100, C424S183100

Reexamination Certificate

active

07445802

ABSTRACT:
Conjugates of the enzyme alliinase with a protein carrier that targets the alliinase to specific cells are used in combination with alliin to produce allicin at a desired target site. The enzyme converts alliin to allicin at the target site to kill cancer cells or pathogens.

REFERENCES:
patent: 4376110 (1983-03-01), David et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5091513 (1992-02-01), Huston et al.
patent: 5096815 (1992-03-01), Ladner et al.
patent: 5122368 (1992-06-01), Greenfield et al.
patent: 5137877 (1992-08-01), Kaneko et al.
patent: 5514554 (1996-05-01), Bacus
patent: 5645835 (1997-07-01), Fell, Jr. et al.
patent: 5861156 (1999-01-01), George et al.
patent: 5863745 (1999-01-01), Fitzgerald et al.
patent: 5965131 (1999-10-01), Griffiths et al.
patent: 6008319 (1999-12-01), Epstein et al.
patent: 6299876 (2001-10-01), Bagshawe
patent: 6312694 (2001-11-01), Thorpe et al.
patent: 6689588 (2004-02-01), Mirelman et al.
patent: 0 171 496 (1986-02-01), None
patent: 0 173 494 (1988-05-01), None
patent: 0 184 187 (1988-06-01), None
patent: 0 302 473 (1989-02-01), None
patent: 0 506 124 (1992-09-01), None
patent: 0 554 441 (1999-01-01), None
patent: WO 87/02671 (1987-05-01), None
patent: WO 86/01533 (1988-03-01), None
patent: WO 91/03134 (1991-06-01), None
patent: WO 91/09134 (1991-06-01), None
patent: WO 97/39115 (1997-10-01), None
patent: WO 97/39115 (1997-10-01), None
Miron et al (Mol Cancer Ther, 2003, 2:1295-1301).
Arditti et al (Mol Cancer Ther, 2005, 4:325-331).
Topp et al (J of Controlled Release, 1998, 53:15-23).
Badruddoja et al (Frontiers in Bioscience, 2006, 11:1466-1478).
Hirsch et al (Nutrition and Cancer, 2000, 38:245-254, IDS).
Stratagene catalog 1988, p. 39.
Miron et al (Mol Cancer Ther, 2003, 2:1295-1301).
Arditti et al (Mol Cancer Ther, 2005, 4:325-331).
“The Totally Garlic Ezine”, Jul. 2000, p. 1-6.
Anon “Sniffing out the benefits of garlic,”Chemistry and Industry20: 815 (Oct. 20, 1997), Abstract on Database SCISEARCH on STN, AN 97:86967.
Barone et al. “Isolation, purification, identification, synthesis and kinetics of activity of the anticandidal component of Allium sativum and a hypothesis for its mode of action,”Mycologia69 (4): 793-825 (1977), Abstract on Database CAPLUS on STN, AN 1977:594680.
Cavallito et al. “Allicin, the Anitbacterial Principle of Allium Sativum. I. Isolation, physical properties and antibacterial action,”J. Am. Chem. Soc.66: 1950-1951 (1944), Abstract on Database CAPLUS on STN, AN 1945:1954.
Cheng et al. “Effect of allithiamine on sarcoma- 180 tumor growth in mice,”T'ai-wan I Hsueh hui Tsa Chih, 80 (4): 385-393 (1981), Abstract on Database CAPLUS on STN, AN 1981:597366.
Gannon “Garlic shown to be effective therapy for heart conditions,”Drug Topic135 (10): 36-39 see especially pate 38 (May 20, 1991).
Hirsch et al. “Effect of Purified Allicin, the Major Ingredient of Freshly Crushed Garlic, on Cancer Cell Proliferation,”Nutrition and Cancer28 (2): 245-254, see especially the Abstract, pp. 245-246, 250 and paragraph bridging pp. 252-253 (2000).
Holzhey et al. “Use of allicin-urotropin as an internal drug for the treatment of infection and cancer,”DE 4024155 A1(Feb. 6, 1992), Abstract on Database CAPLUS on STN, AN 1922:2201109.
Jin et al. “Identification of an Essential Tryptophan Residue in Alliinase from Garlic (Allium sativum) by Chemical Modification,”Buil. Korean Chem. Soc.22(1):68-76 (2001).
Manabe et al. “Alliinase [S-alk(en)yl-Lcysteine sulfoxide lyase] fromAllium tuberosum(Chinese chive), Purification, localization, cDNA cloning and heterologous functional expression,”Eur. J. Biochem.257: 21-30 (1998).
Sakahara et al. “Immunoscientigraphy of Colorectaq1-Cancer using In-111-labeled monoclonal antibody to mucin,”Cancer Immunology Immunotherapy41 (3): 157-161, Abstract on Database SCISEARCH on STN, AN 95:705478.
Springer et al. “Ablation of Human Choriocarcinoma Xenografts in Nude Mice by Antibody-Directed Enzyme Prodrug Therapy (ADEPT) with Three Novel Compounds,”Eur. J. Can.27 (11): 1361-1362 and p. 1366, col.1.
Van Damme et al. “Isolation and characterization of alliinase cDNA clones from garlic Alliium sativum L. and related species,”Eur. J. Biochem(Jun. 18/Aug. 14, 1992) 751-757.
Tzahar et al, “A Hierarchical Network of Interreceptor Interactions Determines Signal Transduction by Neu Differentiation Factor/Neuregulin and Epiderman Growth Factor,”Molecular and Cellular Biology, 16(10):5276-5287 (1996).
Van Damme et al, “Isolation and Characterization of Alliinase cDNA Clones from Garlic (Allium Sativum L.) and Related Species,”Eur J. Biochem209 (2):751-757 (1992).
Sun, et al, “Chimeric Antibody With Human Constant Regions and Mouse Variable Regions Directed Against Carcinoma-Associated Antigen 17-1A,”Proc Natl. Acad. Sci. 84: 214-218 (1997).
Stroll et al, “Chemical Investigations on Aliin, the Specific Principle of Garlic,”Adv Enzymol11:377-401 (1951).
Stancovski, et al, “Mechanistic Aspects of the Opposing Effects of Monoclonal Antibodies to the ERBB2 Receptor on Tumor Growth,”Proc. Natl. Sci. USA88:8691-8695 (991).
Sahagan, et al, “A Genetically Engineered Murine/Human Chimeric Antibody Retains Specificity for Human Tumor-Associated Antigen,”The Journal of Immunology137:1066-1074 (1986).
Park et al, “Characteristics of Cell Lines Established from Human Gastric Carcinoma,”Cancer Research50:2773-2780 (1990).
Pinkas-Kramarski et al, “Diversification of Neu Differentiation Factor and Epidermal Growth Factor Signaling by Combinatorial Receptor Interactions,”The EMBO Journal15(10):4252-2467 (1996).
Rabinkov et al, “Alliinase (Alliin Lyase) from Garlic (Alliium Sativum) is Glycosylated at ASN146and Forms a Complex With a Garlic Mannose-Sepcific Lectin,”Glycoconjugate Journal12:690-698 (1995).
Neuberger et al, “A Hapten-Specific Chimaeric IgE Antibody with Human Physiological Effector Function,”Letters to Nature314(21):268-270 (1985).
Nag et al, “A Colorimetric Assay for Estimation of Polyethylene Glycol and Polyethylene Glycolated Protein Using Ammonium Ferrothiocyanate,”Analytical Biochemistry237: 224-231 (1996).
Morrison et al, “Chimeric Human Antibody Molecules: Mouse Antigen-Binding Domains with Human Constant Region Domains,”Proc. Natl. Acad. Sci. USA6851-6855 (1984).
Miron et al, “A Spectrophotometric Assay for Allicin and Alliinase (Alliin Lyase) Activity: Reaction of 2-Nitro-5-Thiobenzoate With Thiosulfinates,”Analytical Biochemistry265:317-325 (1998).
Miron et al, “A Simplified Method for the Preparation of Succinimidyl Carbonate Polyethylene Glycol for coupling to Proteins,”Bioconi Chemistry4:568-569 (1993).
Meinkoth et al, “Hybridization of Nucleic Acids Immobilized on Solid Supports,”Analytical Biochemistry138:267-284 (1984).
Mckinney et al, “A Simple, Non-Chromatographic Procedure to Purify Immunoglobulins from Serum and Ascites Fluid,”Journal of Immunological Methods96:271-278 (1987).
Makheja et al, “Antiplatelet Constituents of Garlic and Onion,”Agents and Actions29(3/4):360-363 (1990).
Liu et al, “Chimeric Mouse-Human IgG1 Antibody that can Mediate Lysis of Cancer Cells,”Proc. Natl. Acad. Sci. USA84:3439-3443 (1987).
Abramovitz et al, “Allicin-Induced Decrease in Formation of Fatty Streaks (Atherosclerosis) in Mice Fed a Cholesterol-Rich Diet,”Coronary Artery Dis10:515-519 (1999).
Augusti et al, “Lipid Lowering Effect of Allicin (Diallyl Disulphide-Oxide) on long term feeding to Normal Rats,”Experientia30:468-470 (1974).
Better et al, “Escherichia ColiSecretion of an Active Chimeric Antibody Fragment,”Science240:1041-1043. (1988).
Bordia et al, “The Protective Active of Essential Oil

Affiliated with

Also associated with

Rating

Site-specific in situ generation of allicin using a targeted... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Site-specific in situ generation of allicin using a targeted..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Site-specific in situ generation of allicin using a targeted... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4036730